Krystal Biotech had its Relative Strength (RS) Rating upgraded from 64 to 74 Tuesday — a welcome improvement, but still below the 80 or higher score you look for.
This unique rating measures market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an 80 or higher RS Rating as they launch their largest runs. See if Krystal Biotech can continue to show renewed price strength and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Krystal Biotech is not currently offering a proper buying opportunity. See if the stock goes on to form a base that could launch a new move.
Earnings growth increased last quarter from 0% to 407%. But sales fell from 879% to 116%. The company is expected to report its latest numbers on or around May 12.
The company holds the No. 5 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
